MAPT and Alzheimer disease: There is sufficient evidence that plasma p-tau fulfils the criteria for full achievement in identifying AD (phase 2; primary aim 1), early disease (phase 3; primary aim 1) and has tissue-biofluid association (phase 2; secondary aim 2).